Kristel Carrington

Company: Sama Therapeutics

Job title: Chief Medical Officer

Seminars:

Transprognostic Biomarkers from Bench to Bedside: An AI-Powered Multimodal Platform for Precision Neuropsychiatry Trials 3:40 pm

The fall and rise again of neuropsychiatric drug discovery, reviewing historical challenges and emerging opportunities Limitations of DSM-based phenotypes VS utilizing endophenotypes to close the translational gap via multimodal, evolutionarily preserved biomarkers for objective readouts Opportunities presented by the psychedelic renaissance to integrate subjective experience with real time, state-based biosensing for predictive biomarker developmentRead more

day: Conference Day One